Novo Nordisk is eyeing domestic diabetes market

Published: 2007-10-22 06:56:00

Updated: 2007-10-22 06:56:00

Novo Nordisk Korea is intensifying heated marketing efforts on a new long-acting insulin analogue Levemir (insulin detemir) to strengthen its presence in local diabetes market.

Levemir is a long-acting basal insulin analog indicated for once- or twice-daily subcutaneous administration for the treatment of adults and children with type 1 diabetes mellitus and adult patients with type 2 diabe...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.